Antipsychotic dosing: How much but also how often?

Schizophrenia Bulletin

Volumn 36, Issue 5, 2010, Pages 900-903

  Remington, Gary ^a,b   Kapur, Shitij ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

antipsychotics; dose; dosing schedule; tolerance

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE;

COST CONTROL; DRUG ACTIVITY; DRUG EFFICACY; DRUG EXPOSURE; HUMAN; LOCOMOTION; METABOLIC DISORDER; MOTOR ACTIVITY; NONHUMAN; PATIENT COMPLIANCE; PHYSICIAN; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; RELAPSE; RISK FACTOR; SCHIZOPHRENIA; SHORT SURVEY; STEADY STATE; TREATMENT RESPONSE; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; DYSKINESIA, DRUG-INDUCED; HUMANS; LONG-TERM CARE; RATS; RECEPTORS, DOPAMINE D2; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 77955931468     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbq083     Document Type: Short Survey

References (28)

1. 2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry. 2001;50:873-883.
2. 2occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157:514-520.
3. 2 receptor occupancy of clo-zapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156:286-293.
4. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull. 1993;19:287-302.
5. Weiden PJ. Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry. 2007;68(suppl 14):14-19.
6. 2 receptor occupancy. Arch Gen Psychiatry. 2000;57:553-559.
7. 2 receptor occupancy for the management of schizophrenia. J Clin Psychiatry. 2008;69:1281-1286.
8. Boshes RA, Manschreck TC. Review of antipsychotic medication administration: a proposal of intermittent dosing. Schizophr Bull. 2002;28:203-222.
9. Lerner V. High-dose olanzapine for treatment-refractory schizophrenia. Clin Neuropharmacol. 2003;26:58-61.
10. Prien RF, Gillis RD, Caffey EM, Jr. Intermittent pharmaco-therapy in chronic schizophrenia. Hosp Community Psychiatry. 1973;24:317-322.
11. Gaebel W. Intermittent medication\an alternative? Acta Psychiatr Scand. 1994;89(suppl 382):33-38.
12. Remington G, Seeman P, Shammi C, Mann S, Kapur S. "Extended" antipsychotic dosing: rationale and pilot data. J Clin Psychopharmacol. 2005;25:611-613.
13. Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia. J Clin Psychiatry. In press.
14. Post RM. Intermittent versus continuous stimulation: effect of time interval on the development of sensitization or tolerance. Life Sci. 1980;26:1275-1282.
15. Carey RJ, DeVeaugh-Geiss J. Treatment schedule as a determinant of the development of tolerance to haloperidol. Psy-chopharmacology (Berl). 1984;82:164-167.
16. 2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. Neuropsychopharmacology. 2003;28:1433-1439.
17. Turrone P, Remington G, Kapur S, Nobrega JN. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol Psychiatry. 2005;57: 406-411.
18. Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry. 2008;64:145-152.
19. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. " Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007;27:2979-2986.
20. 11C]-raclopride PET study in cats. Neuropsychopharmacology. 2009;34:662-671.
21. Lieberman J, Jody D, Geisler S, et al. Treatment outcome of first episode schizophrenia. Psychopharmacol Bull. 1989;25: 92-96.
22. Remington GJ, Prendergast P, Bezchlibnyk-Butler KZ. Neu-roleptic dosing in chronic schizophrenia: a 10-year follow-up. Can J Psychiatry. 1997;42:53-57.
23. Yamin S, Vaddadi K. Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clo-zapine. Int Rev Psychiatry. 2010;22:138-147.
24. Stip E, Tourjman V, Lew V, et al. "Awakenings" effect with risperidone. Am J Psychiatry. 1995;152:1833.
25. Davis JM, Matalon L, Watanabe MD, Blake L. Depot anti-psychotic drugs. Place in therapy. Drugs. 1994;47:741-773.
26. Chouinard G, Jones BD. Neuroleptic-induced supersensitiv-ity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry. 1980;137:16-21.
27. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (super-sensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand. 2006;114:3-13.
28. Muller P, Seeman P. Dopaminergic supersensitivity after neu-roleptics: time-course and specificity. Psychopharmacology (Berl). 1978;60:1-11.